Developments Revive gets FDA orphan drug nod for Bucillamine in IRI during liver transplant Revive Therapeutics (OTCQB:RVVTF; CSE:RVV; FRANKFURT:31R) received orphan drug designation from the FDA for Bucillamine for the prevention of ischemia–reperfusion injury (IRI) during liver transplantation. ... February 15, 2022